Latest / Lung Cancer Considered
FDA Approval: Telisotuzumab Vedotin and MET-Positive NSCLC
In this episode, we will discuss the FDA approval of telisotuzumab vedotin, an antibody drug conjugate, for NSCLC with high c-MET expression. To help review the data and offer perspective on this new agent, I am joined by two expert thoracic oncologists. I want to welcome Dr. Mor Moskovitz, Head of the Thoracic Medical Oncology Service at Davidoff Cancer Center at the Rabin Medical Center in Petah Tikva, Israel.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.